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intraocular lens (IOL) is currently the preferred tech-
nique among cataract surgeons  [2] . The procedure is ef-
ficient, and uneventful surgery is generally associated 
with good visual results  [3–5] . Nevertheless, cystoid mac-
ular edema (CME) may develop, and this can result in 
suboptimal postoperative vision  [6–8] . It can occur after 
uncomplicated surgery in patients with otherwise healthy 
eyes, after complicated surgery, or after surgery in pa-
tients with ocular diseases such uveitis or diabetic reti-
nopathy  [9] .
 CME following cataract surgery was initially reported 
by Irvine in 1953 and demonstrated angiographically by 
Gass and Norton in 1966, so it is known as the Irvine-
Gass syndrome  [10–12] .
 Angiographic CME is diagnosed in patients who are 
otherwise asymptomatic with respect to visual acuity, but 
have detectable leakage from the perifoveal capillaries on 
fluorescein angiography (FA). Clinical CME is diagnosed 
in those patients who have detectable visual impairment 
as well as angiographic and/or biomicroscopic findings.
 The clinical diagnosis is confirmed using optical co-
herence tomography (OCT) and FA.
 The incidence of pseudophakic CME depends on the 
methodology used in its detection.
 The prophylactic use of non-steroidal anti-inflamma-
tory drugs (NSAIDs) preoperatively, and the combina-
tion of steroids and NSAIDs in the postoperative period, 
is recommended to reduce the incidence of pseudophakic 
CME.
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 Abstract 
 Cataract surgery is an efficient procedure, and is generally 
associated with good visual results. Nevertheless, cystoid 
macular edema (CME) may develop, and this can result in 
suboptimal postoperative vision. Many factors are consid-
ered to contribute to its development, and although the 
treatment options depend upon the underlying cause of 
CME, the usual therapeutic approach for prophylaxis and 
treatment of CME is directed towards blocking the inflam-
matory mediators. This article provides a review of possible 
risk factors, pathogeneses, incidence rates, and methods of 
diagnosis, as well as the current guidelines for managing 
CME.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Cataract extraction is one of the most commonly per-
formed surgeries. Over recent years, it has benefited from 
consistent innovations in instrumentation, lens design, 
and surgical technique that have led to improved out-
comes following cataract surgery  [1] . Phacoemulsifica-
tion using small incisions and implantation of a foldable 
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 Etiology and Risk Factors 
 The specific etiology of aphakic and pseudophakic 
macular edema is not fully understood. Many factors 
have been considered to contribute to its development, 
such as the type of cataract surgery, light toxicity, vitreo-
macular traction, inflammatory mediators, use of adren-
ergic drugs, age, vitreous loss, integrity of the posterior 
capsule, hypertension, and diabetes  [7, 13] .
 The type of cataract surgery used is associated with 
different outcomes and complications, such as CME.
The change in procedure from large-incision intracap-
sular cataract extraction to small-incision extracapsular 
phacoemulsification was associated with a clear decrease 
in the incidence of this complication  [7, 13–18] . This has 
been explained by less blood-aqueous barrier damage af-
ter phacoemulsification with an intact continuous curvi-
linear capsulorhexis than after extracapsular cataract ex-
traction  [19, 20] .
 Although microscope light toxicity has been indicated 
to be a possible contributor to CME, a prospective ran-
domized study did not support this finding, and showed 
no statistically significant difference in the rate of angio-
graphic CME from using a pupillary light occluder  [21] . 
However, IOLs that filter UV light may reduce the rate of 
angiographic CME  [22] .
 The age of the patients is another factor that needs to 
be considered. Some authors have indicated a positive 
correlation with age, demonstrating an increased inci-
dence of CME in older patients  [7, 23] .
 Changes occurring in the vitreous body during surgery 
are another pathogenic mechanism that has been pro-
posed as a cause of CME development. Although CME 
can occur after uneventful cataract surgery, certain surgi-
cal complications raise the risk of CME. Rupture of the 
posterior capsule as well as secondary capsulotomy (in-
cluding YAG laser capsulotomy) are associated with a 
higher rate of CME  [24] . Vitreous loss increases the prev-
alence of CME by 10–20%  [7, 25, 26] . Different studies 
have confirmed that the rate of clinical CME associated 
with vitreous loss is higher compared to cases without this 
complication after either extracapsular cataract extrac-
tion or phacoemulsification  [25, 27–29] . The lower rate of 
CME occurring when there is vitreous loss during phaco-
emulsification has also been explained by the small wound 
construction and greater stability in this type of surgery 
compared with large-incision cataract surgery  [17, 30–32] . 
Vitreous to the wound prolongs CME, and can be associ-
ated with a poorer prognosis  [26] . Iris incarceration, an 
additional risk factor for CME, may have a more impor-
tant association with poor vision in patients with chronic 
postsurgical CME than with other intraoperative compli-
cations  [24, 33] . Retained lens fragments, even when they 
are removed by pars plana vitrectomy, are another com-
plication associated with an increased rate of CME and 
more severe visual loss, in eyes with a sulcus fixated pos-
terior chamber IOL, anterior chamber IOL, or aphakic 
eyes  [34–37] . Retained lens fragments cause inflamma-
tion that is often severe, and these eyes have longer cata-
ract surgery times than eyes with uneventful cataract ex-
traction. Prolonged exposure to light from the operating 
microscope during the initial surgery combined with pos-
sible pars plana vitrectomy, as a second surgery, may also 
contribute to a higher incidence of CME  [38, 39] .
 There are multiple reports about the association of 
CME after cataract surgery with the topical use of latano-
prost, an ocular hypotensive lipid that is a prostaglandin 
analogue agent  [40–43] . Other similar agents (unopros-
tone, travoprost and bimatoprost) were also associated 
with an increased incidence of CME  [44] . The explanation 
of the increased incidence of CME associated with the 
prostaglandin analogues is based on the associated in-
crease in blood-aqueous barrier disruption and inflamma-
tory activity. Considering this possibility, it is recommend-
ed to avoid or discontinue this medication and substitute 
it for another type of hypotensive drug before surgery.
 In diabetic patients, CME shows an increase risk, espe-
cially in patients with pre-existing diabetic retinopathy 
 [45] . The incidence of CME in diabetic patients, even in the 
absence of diabetic retinopathy, is higher than in patients 
without this pathology  [46] . Although the frequency of this 
problem has decreased with the widespread use of smaller 
incisions and phacoemulsification, it remains an impor-
tant issue to consider  [47] . The poor visual acuity after cat-
aract surgery in these patients due to macular edema is 
common, and the two clinical forms (diabetic macular 
edema and edema caused by Irvine-Gass syndrome) prob-
ably co-exist  [45, 48, 49] . These are difficult to differentiate, 
although some authors have suggested that if there is post-
operative hyperfluorescence of the optic disc in the angio-
grams, it probably corresponds to a CME which would be 
likely to resolve spontaneously  [50] . It is very important to 
take into consideration that if the patient has already some 
degree of macular edema when the cataract surgery is con-
sidered, it should be treated before the surgery and – in 
cases when this is not possible – intravitreal anti-inflam-
matory medication at the surgical time may be used.
 Certain patients appear to have a higher risk of CME 
after cataract surgery. Patients with uveitis frequently de-
velop CME, and it is the most common reason for poor 
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outcomes of cataract surgery in these patients  [51] . After 
cataract surgery in patients with juvenile rheumatoid ar-
thritis or pars planitis, the occurrence of CME can reach 
an incidence of about 50%  [52] . Foster et al.  [53] reported 
similar incidences in a retrospective study with uveitis 
patients. Other studies have reported lower incidences of 
CME. It is important to note that there is a wide variation 
in severity of uveitis, and surgeons should consider these 
patients at risk of postoperative CME. Taking this into 
account, it is imperative to control preoperative inflam-
mation and introduce postoperative medication accord-
ing the expected risk.
 In conclusion, the most frequent risk factors associated 
with pseudophakic CME are iris trauma, rupture of pos-
terior capsule, vitreous loss or incarceration, dislocated 
IOL, use of iris fixed lenses, active uveitis, and diabetes.
 Pathogenesis 
 The pathogenesis of CME following cataract surgery 
remains uncertain, but clinical observations and experi-
mental studies indicate that the pathophysiology of this 
postoperative problem may be multifactorial  [26, 39] . 
Among the factors of potential clinical importance are 
vitreous traction  [10, 54] , functional disturbance of the 
blood-retinal barrier (BRB)  [13, 55–57] , and inflamma-
tion mediated by prostaglandins  [7, 39, 58–62] . Most in-
vestigators consider inflammation as the major etiologic 
factor in the development of CME following cataract sur-
gery. It is noteworthy that inflammation is directly associ-
ated with a breakdown of the BRB. It is probable that after 
surgery the inflammation mediators (prostaglandins, cy-
tokines, and other vascular permeability factors) are re-
leased from the anterior segment of the eye and diffuse to 
the vitreous cavity and retina, stimulating the breakdown 
of the BRB and subsequent leakage of fluids across the 
retinal vessel wall and through the retinal pigment epithe-
lium (RPE) into perifoveal retinal tissues resulting in 
macular edema  [13, 63, 64] . Surgical manipulation, which 
happens during the cataract surgery, always causes trau-
ma to the iris. It is known that the iris is a metabolically 
active tissue that releases inflammatory mediators when 
traumatized. After surgery, the physiological healing pro-
cess is sufficient to slowly, but progressively, suppress the 
inflammation  [65] . In about 90% of patients with macular 
edema following cataract surgery, a spontaneous resolu-
tion of the edema and a recovery of visual acuity can be 
observed. In specific situations, an excessive leakage oc-
curs, which can lead to a severe and irreversible impair-
ment of visual acuity. The different degrees of leakage ex-
plain the higher incidence of angiographically detectable 
CME compared to clinically identified CME  [66] .
 The inflammatory mediators probably play the essen-
tial initiating role in the development of inflammatory 
CME, but the exact factors and events responsible for fur-
ther CME development and its chronicity have not yet 
been clearly identified.
 Incidence 
 Though the rate of CME has been declining with de-
creasing surgical incision and the use of microsurgical 
instrumentation, the high volume of cataract surgeries 
performed each year makes CME a common cause of 
poor vision in pseudophakic patients  [32] .
 Determining the overall incidence of CME has been 
difficult because of variations in the patient populations 
evaluated (with varying risk factors) and the use of dif-
ferent methods for evaluating macular thickening. An-
other factor that contributes to the uncertain incidence is 
the use of different prophylactic medications before and 
after cataract surgery. There are multiple reports com-
paring the incidence of clinical and angiographic CME 
under specific anti-inflammatory drugs  [67–69] . The 
multiple reports and reviews that mention or discuss the 
incidence of CME show different numbers and the expla-
nations are, in certain cases, unclear  [26, 70] . However, it 
is important to recognize the many variables involved 
and the difficulty in identifying their potential impact on 
the interpretation of results from therapeutic trials that 
evaluated potential treatments for CME.
 The true current incidence of clinical CME using mod-
ern techniques appears to be very low in uncomplicated 
cases. It is likely to be in the range of 0.2–2%, and the rate 
of angiographic CME is at least ten-fold higher in magni-
tude  [26, 32, 71] . These numbers increase if another large-
incision technique is required, instead of small-incision 
phacoemulsification with implantation of a foldable IOL; 
they also increase if we have a complicated surgery with 
iris trauma, or capsule rupture with vitreous loss, or in pa-
tients at high risk (such as those with uveitis or diabetes).
 Diagnosis 
 The diagnosis of CME can generally be made on clin-
ical examination with evidence of perifoveal cystic spac-
es, and has traditionally been confirmed with use of FA 
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to document the classic petaloid pattern of leakage in-
duced by inflammatory mediators that lead to break-
down of the BRB. Today, the most definite evidence is 
obtained from OCT examination.
 Signs and symptoms of clinically significant CME 
typically develop 4–12 weeks after surgery and reach a 
peak at 4–6 weeks postoperatively. The patient may com-
plain of impaired vision after an initial period of im-
proved vision  [24] . Generally, this responds to treatment 
with topical anti-inflammatory medications and usually 
resolves within 6 months. However, some cases respond 
poorly to conservative treatment, persist for more than 6 
months, and may develop permanent visual loss. Al-
though the incidence of chronic CME is much less fre-
quent, being reported at 1–2% of uncomplicated cases 
and about 8% after complicated cataract surgery, the as-
sociated vision loss makes it a serious complication.
 In ophthalmoscopy and biomicroscopy, the loss of fo-
veal depression is the most frequent sign of CME. Intra-
retinal cystoid spaces can be detected and the perifoveal 
area can appear with a yellowish coloration  [7, 24, 32] . A 
swelling of the optic nerve head can be detectable  [26] . In 
cases of chronic CME, the cystoid spaces fuse to foveal 
cysts.
 Angiographic CME is diagnosed in patients who are 
otherwise asymptomatic with respect to visual acuity, but 
have detectable leakage from perifoveal capillaries on FA 
demonstrated by hyperfluorescence in the central macu-
la and optic disc. Clinical CME is diagnosed in those pa-
tients who have detectable visual impairment as well as 
angiographic and/or biomicroscopic findings  [32, 72] .
 In the early phase of the FA, capillary dilatation and 
leakage from small perifoveal capillaries are visible. In 
later phases, pooling in the outer plexiform layer results 
in the classic perifoveal ‘petaloid’ staining pattern. An-
other common sign is late leakage and staining of the op-
tic nerve due to capillary leakage  [73] . In severe CME, the 
cystoid spaces may have a ‘honeycomb’ appearance in FA, 
corresponding to large cystoid spaces, extending outside 
the immediate perifoveal region  [24] . Vitreous fluorom-
etry, a more sensitive technique for measuring alterations 
in the BRB using fluorescein, shows an even higher inci-
dence of alterations in the period immediately after cata-
ract surgery  [55] . The retinal leakage analyzer is a meth-
odology that can be used to objectively measure the dis-
ruption of the blood-retinal barrier, leading to a 
quantitative evaluation of the macular edema  [74] .
 With OCT, it is possible to observe the cystic spaces in 
the outer nuclear layer of the central macula and, in cor-
relation with histological findings, measure the edema 
which should correspond to the value of the observed ret-
inal thickening  [75–77] . The foveal thickness can increase 
significantly, and it correlates moderately with the de-
crease in visual acuity, but clearly better than the correla-
tion between FA and visual acuity.
 Although the FA has been considered the diagnostic 
gold standard for pseudophakic CME, OCT is now the 
method of choice, being a non-invasive technique to eval-
uate and follow CME after cataract surgery  [78] . An ad-
ditional advantage of the use of OCT is that the thicken-
ing of macular area effectively measures the edema, and 
therefore correlates better with vision than the angio-
gram grading  [26] .
 Classification 
 Angiographic CME is defined as the presence of fluo-
rescein leakage on FA. It is mostly asymptomatic. A de-
crease in visual acuity does not correlate with an exten-
sion of leakage. Clinically significant CME presents with 
decreased vision, and is generally diagnosed by biomi-
croscopy and OCT.
 Usually the CME appears within 4 months of surgery, 
and is designed as acute. If the onset occurs after more than 
4 months postoperatively, it is designed late-onset CME.
 The CME is classified as chronic if it lasts more than 6 
months.
 Management 
 Angiographic CME after cataract surgery is not neces-
sarily associated with poor visual outcome. Usually it re-
solves spontaneously and only about 1–3% of cases per-
sist, and this corresponds to clinical CME with persistent 
symptoms  [79] .
 It is now accepted that in cataract surgery it is impor-
tant to perform a therapeutic intervention both for pro-
phylaxis and for treatment of CME based on the existing 
knowledge of its pathogenesis. Many of the multiple stud-
ies performed to test the efficacy of different drugs in 
pseudophakic CME have been poorly designed. There-
fore, the results are not consistent and controversy per-
sists. However, it is now widely accepted that it is impor-
tant to introduce anti-inflammatory drugs not only to 
treat but also specifically to prevent the development of 
CME after cataract surgery  [80, 81] .
 Although the treatment options depend on the under-
lying cause of CME, the usual therapeutic approach for 
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the prophylaxis and treatment of CME is directed to-
wards blocking the inflammatory mediators, mainly the 
prostaglandins in the anterior segment of the eye, using 
topical steroids and NSAIDs.
 Topical NSAIDs have demonstrated effectiveness in 
preventing both angiographic and clinical CME  [68] . 
There are multiple reports concerning the use of different 
NSAIDs in the prevention and treatment of CME. In gen-
eral, studies have proven the effectiveness of use of this 
type of medication, and without clear statistical differ-
ences between the different NSAIDs.
 Corticosteroids are effective, but they can cause an in-
crease in intraocular pressure in a small percentage of 
patients. Usually the medical treatment of uncomplicated 
cases can first include NSAIDs with, in some cases, the 
addition of topical steroids. Clinical evidence suggests 
that the combined use of NSAIDs and steroids is syner-
gistic  [82, 83] .
 In patients with evidence of anterior segment inflam-
mation or those with chronic CME following posterior 
capsule trauma, steroids have been shown to be effec-
tive, and a stepwise plan may be undertaken starting 
with topical administration, followed by local injection, 
reserving high-dose intra-vitreous administration for 
severe refractory cases. This can reduce macular edema 
and improve vision in eyes with CME that persists or 
recurs despite previous medical treatment  [84–86] . 
However, CME may recur in some cases, even after 
more than one intravitreal injection of triamcinolone 
acetonide.
 A carbonic anhydrase inhibitor (acetazolamide) may 
help reduce the edematous component. These have the 
ability to stimulate the RPE to pump excess fluid out of 
the macula. Furthermore, carbonic anhydrase inhibitors 
induce acidification of the subretinal space, and thereby 
increase fluid resorption from the retina through the 
RPE into the choroid  [24, 87] . There are some reports 
documenting the positive effect of acetazolamide in post-
surgical CME  [88] .
 The use of antiangiogenic agents has also been pro-
posed as an alternative therapeutic approach in some cas-
es of refractory CME. VEGF, a potent inducer of altera-
tions in the BRB, may be increased in postoperative CME. 
However, bevacizumab, a monoclonal antibody against 
all isoforms of VEGF, which has been used to treat some 
neovascular diseases, was used in patients with postop-
erative CME without positive effects  [89] .
 Vitreolysis using the Nd:YAG laser has shown positive 
effects in cases of vitreous incarceration in the cataract 
incision wound  [90] .
 Surgical treatment, namely vitrectomy, is indicated in 
some specific cases of chronic CME and appears to be ef-
fective. The rationale for performing vitrectomy in CME 
following surgery includes the removal of vitreous adhe-
sions and inflammatory mediators and improved access 
of topical medication to the posterior pole.
 The current guidelines for managing post-cataract 
surgery inflammation state that the prevention of in-
flammation should be the main goal, with good patient 
selection, correct eye/patient preparation, taking special 
care during surgery not to cause iris trauma, appropriate 
resolution of intraoperative complications, and timely 
treatment of postoperative inflammation  [91] .
 It should be noted that diabetic patients with pre-sur-
gical macular edema have a higher risk of worsening their 
macular edema after cataract surgery. In these patients, 
it is recommended to first treat the macular edema and 
only perform the surgery afterwards. In these cases, the 
use of intravitreal triamcinolone acetonide (4 mg) inject-
ed at the end of cataract surgery is indicated.
 Conclusions/Recommendations for Managing 
Pseudophakic CME 
 • First, it is very important to perform a correct preop-
erative evaluation of the patient. Patients can be di-
vided into normal and high-risk cataract patients. 
 • If s/he is a high-risk patient, the potential for improve-
ment or correction should be considered, and, if indi-
cated, medication should be introduced and the thera-
peutic schema adapted. 
 • If s/he is a normal patient, it is recommended (as pro-
phylaxis) to administer topical NSAIDs during the 
first month in combination with topical steroids, us-
ing decreasing doses during the first 2 weeks. 
 • If there is a recognized CME, first the topical NSAIDs 
and steroids should be re-introduced for 1 month. Af-
ter this, visual acuity should be evaluated and an OCT 
should be performed to estimate any possible im-
provement in the CME. 
 • If the CME has not improved, the introduction of ac-
etazolamide (for 1 month or more) should be consid-
ered, or, as an alternative, a periocular corticosteroid 
or intravitreal triamcinolone. 
 • If there is vitreous incarceration or a persistent in-
flammatory reaction, surgery it (vitrectomy) should 
be considered. 
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